Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Clinically Diagnosed Tauopathies in Comparison to Healthy Subjects

NCT02103894 is registered in ClinicalTrials.gov with Molecular NeuroImaging as lead sponsor.

NCT NCT02103894
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02103894 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Clinically Diagnosed Tauopathies in Comparison to Healthy Subjects
Lead sponsor
Molecular NeuroImaging
Phase
Phase 1
Overall status
Completed
Start date
February 28, 2014
Completion date
September 30, 2016
Enrollment
16 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease (ad), chronic traumatic encephalopathy (cte), frontal temporal dementia (ftd), parkinson's disease (pd), pick's disease, progressive supranuclear palsy (psp), tauopathies